Depression Rises as Other Head and Neck Cancer Symptoms Ease
11/05/2026
Key Takeaways
- Among patients with head and neck cancer in a UK cohort, depression increased while anxiety, fear of recurrence, and oral pain generally decreased.
- Younger age, lower income, and greater weekly alcohol use were associated with elevated symptom-class membership.
- HPV-positive disease was associated with faster within-class decreases in anxiety and recurrence fear but a greater within-class increase in depression than HPV-negative disease.
The analysis included 5,411 newly diagnosed adults from the observational Head and Neck 5000 cohort, recruited at clinics in England, Wales, and Scotland from 2011 to 2014. Assessments occurred at diagnosis, 4 months, 12 months, and 36–60 months; the mean final-assessment time was 48 months, and 2,263 people completed that assessment. The Hospital Anxiety and Depression Scale (HADS) measured anxiety and depression. Fear of Cancer Recurrence-4 (FCR-4) measured recurrence fear beginning at 4 months, not diagnosis, and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module oral-pain subscale measured pain. Separate three-class latent class growth analyses identified mild, moderate, and elevated trajectories for each symptom; two-class growth mixture models assessed within-class change. Class selection considered fit and separation, and full-information maximum likelihood handled missing data under a missing-at-random assumption.
In the primary trajectory models, the largest depression class had mild symptoms (58%), as did the largest anxiety class (48%). Depression increased across all three depression classes. Anxiety generally eased, but the elevated anxiety class remained high without significant change. Younger age, lower income, and greater weekly alcohol use were consistently associated with membership in elevated symptom classes. These associations describe group membership, not the causes of individual symptom changes.
Oral pain's largest class was mild (62%), whereas fear of recurrence's largest class was moderate (44%). Elevated classes accounted for 10%–18% within each symptom domain; the analyses did not establish that the same people belonged to elevated classes across domains. Recurrence fear and oral pain generally decreased. Compared with human papillomavirus (HPV)-negative disease, HPV-positive disease was associated with faster within-class decreases in anxiety and recurrence fear and, within the moderate-depression class, lower depression at diagnosis but a greater increase over time. HPV status did not significantly predict class membership. Advanced-stage disease was associated with elevated depression, recurrence-fear, and oral-pain classes, while current or former tobacco use was associated with elevated anxiety and oral-pain classes.
Follow-up attrition makes interpretation dependent in part on the missing-at-random assumption. Historical enrollment, limited assessment points, and limited demographic detail also constrain how the observed courses may apply today. HADS may not fully separate anxiety from depression, and statistically defined classes can change with model specification rather than represent discrete patient types. These observational associations cannot establish causes or show that screening, supportive care, or behavioral interventions improve outcomes; the authors raised such approaches as possibilities, not tested benefits.
For long-term survivors, these divergent symptom courses and associations with elevated classes describe group-level patterns, not causal explanations or validated individual predictions.
Clinician Questions
Which patients were excluded from the UK head and neck cancer symptom-trajectory cohort?
The UK Head and Neck 5000 cohort excluded people with recurrent head and neck cancer, primary lymphoma, primary skin cancer, no head and neck cancer, or without the mental capacity to provide informed consent; the observed trajectories do not establish outcomes for those excluded groups.
How did the head and neck cancer analysis define moderate or severe fear of recurrence?
For people with head and neck cancer, Fear of Cancer Recurrence-4 questionnaire scores of at least 10 denoted moderate fear of recurrence, and scores of at least 15 denoted severe fear. These are measurement thresholds, not patient proportions or evidence of a treatment effect.
This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.